Liontown Resources Ltd (ASX: LTR) and Mesoblast Ltd (ASX: MSB) are two of four ASX shares falling on Friday. Here's ...

Mesoblast's FDA approval for remestemcel marks a milestone for MSC therapies, but limited cash reserves pose risks for US ...

Mesoblast Limited (NASDAQ:MESO – Get Free Report)’s share price hit a new 52-week high on Monday . The stock traded as high ...

Latest data shows the largest indicative borrow rate increases among liquid option names include: Mesoblast (MESO) 535.67% +298.96, Aptiv ...

S&P/ASX All Ords Index (ASX: XAO) shares closed higher on the first day of trading for 2025, with these stocks clocking new ...

Remestemcel-L is under clinical development by Mesoblast and currently in Phase III for Crohn's Disease (Regional Enteritis).

These shares are starting the year in a positive fashion. But why? The post Why Brainchip, Fortescue, Mesoblast, and QBE ...

Shares of Mesoblast Limited (NASDAQ:MESO – Get Free Report) fell 5.7% on Friday . The stock traded as low as $17.16 and last traded at $17.25. 88,059 shares were traded during trading ...

Top 2024 performers include multiple health care stocks with unique catalysts, as well as several quantum computing ...

New data shows the 40 key ASX biotechs gained an average 50% in 2024 - but not all of them joined the winner's circle.

The Australian share market is opening for trade again in the new year, with issues such as interest rates, inflation and global politics set to shape markets in 2025. Follow the day's events and ...